![](/img/cover-not-exists.png)
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jiang, Zefei, Li, Wei, Hu, Xichun, Zhang, Qingyuan, Sun, Tao, Cui, Shude, Wang, Shusen, Ouyang, Quchang, Yin, Yongmei, Geng, Cuizhi, Tong, Zhongsheng, Cheng, Ying, Pan, Yueyin, Sun, Yuping, Wang, HongLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(19)30164-0
Date:
April, 2019
File:
PDF, 355 KB
english, 2019